All In Biotech

Drug Trial Radar · NCT03386942

A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors

A Phase 1 Study of MORAb-202 in Subjects With Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

82

Actual

Start

Nov 28, 2017

Primary completion

Oct 26, 2022

Study completion Oct 26, 2022

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Dec 29, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the tolerability and safety profile of farletuzumab ecteribulin in participants with solid tumors.

Conditions

  • Solid Tumors

Interventions

  • Farletuzumab EcteribulinDrug

    Part 1: farletuzumab ecteribulin intravenous (IV) infusion administered every 3 weeks starting at a 0.3 mg/kg dose and successively increasing doses until DLT. Part 2: farletuzumab ecteribulin administered IV every 3 weeks at a dose determined in Part 1 until any of the criteria for discontinuation are met.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of participants with dose-limiting toxicities (DLTs)Time frame: At the end of Cycle 1 (21 days)
  2. Part 1 and Part 2: Number of participants with adverse events (AEs), adverse events of interest (AEIs), and serious adverse events (SAEs)Time frame: Up to 50 months
  3. Number of participants with any clinically significant clinical laboratory test valueTime frame: Up to 50 months
  4. Number of participants with any clinically significant vital sign valueTime frame: Up to 50 months
  5. Change from Baseline in arterial oxygen saturationTime frame: Baseline; up to 50 months
  6. Change from Baseline in body weightTime frame: Baseline; up to 50 months
  7. Number of participants with any clinically significant 12-lead electrocardiogram (ECG) valueTime frame: Up to 50 months
  8. Change from Baseline in the performance status (PS) score established by the Eastern Cooperative Oncology Group (ECOG)Time frame: Baseline; up to 50 months
  9. Change from Baseline in serum anti-drug antibody (ADA) titerTime frame: Baseline; up to 50 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Eisai Trial Site 5

    Matsuyama, Ehime, Japan

  • Eisai Trial Site 6

    Kurume, Fukuoka, Japan

  • Eisai Trial Site 8

    Sapporo, Hokkaido, Japan

  • Eisai Trial Site 4

    Akashi, Hyōgo, Japan

  • Eisai Trial Site 7

    Niigata, Niigata, Japan

  • Eisai Trial Site 3

    Hidaka, Saitama, Japan

  • Eisai Trial Site 9

    Sunto-gun, Shizuoka, Japan

  • Eisai Trial Site 1

    Chuo-ku, Tokyo, Japan

  • Eisai Trial Site 2

    Koto-ku, Tokyo, Japan

  • Eisai Trial Site 10

    Koto-Ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.